After investing into $ARNA in the $2's a while back and selling the entire position in the $11's thereafter, I initiated a position at $5.86 just recently. The bottom line is company will gradually build a consumer base.
The US consumer data clearly states that obesity will continue to increase as society standards of fast food, portion size and quote unquote junk food sales are increasing with population. Yes, $ARNA may not have the proper direction; as the marketing campaign seems rather odd. Yes, they may not even have the best management chemistry; as their actions thus far have seemed to disappoint. Yes they may have a lazy partner as Eisai and $ARNA need to act on the same page, formulate a plan and execute it right, continue to increase exposure which will lead to sales and overtime these figures should dictate a positive future to come. And of course, there are other problems at the moment which is why the short percentage has been high for the past 6 months.
There is a ton of potential long-term. $ARNA, which made the first obesity drug to be approved in the United States in 13 years, has two other drugs in clinical trials - for treating autoimmune diseases and blood-clot related disorders.
The company announced the completion of a Phase 1b clinical trial for APD811, an investigational oral prostacyclin receptor agonist intended for the treatment of pulmonary arterial hypertension . The co plans to initiate a Phase 2 clinical trial for APD811 in the first quarter of 2014. "We believe APD811 is a promising new chemical entity that could improve current patient care by providing an oral option for IP-targeted therapy. Based on the encouraging Phase 1 results, we look forward to initiating the Phase 2 program early next year." No serious adverse events were observed, and the most frequent treatment-emergent adverse events were headache, nausea and jaw pain.
Now of course, on Aug 28 $ARNA stated 1 patient had some problems. Longterm by DEC 2013 $ARNA $9